Published in Br J Pharmacol on March 06, 2016
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists. J Med Chem (2016) 0.76
Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms. Neuropharmacology (2016) 0.75
Cancer and orofacial pain. Med Oral Patol Oral Cir Bucal (2016) 0.75
Purinergic Signalling: Therapeutic Developments. Front Pharmacol (2017) 0.75
Polypharmacology of conformationally locked methanocarba nucleosides. Drug Discov Today (2017) 0.75
Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opin Ther Pat (2017) 0.75
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain (2009) 7.11
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96
Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci (2009) 5.53
Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature (2003) 4.50
The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol (2015) 4.28
The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci (2001) 4.17
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol (2000) 4.06
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature (1997) 3.75
The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal (2006) 3.52
Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci (2002) 3.32
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06
The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol (2015) 2.74
Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem (2001) 2.63
Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol (1996) 2.55
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem (2000) 2.44
Turnover of adenosine in plasma of human and dog blood. Am J Physiol (1989) 2.26
Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys (1996) 2.25
Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol (2000) 2.25
Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A (1993) 2.08
Pain as a global public health priority. BMC Public Health (2011) 1.82
Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci (1998) 1.79
Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci (2002) 1.78
Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol (1996) 1.75
Adenosine receptor activation and nociception. Eur J Pharmacol (1998) 1.74
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
Role of cation-chloride-cotransporters (CCC) in pain and hyperalgesia. Curr Top Med Chem (2005) 1.69
The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol (2015) 1.66
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Alleviating suffering 101--pain relief in the United States. N Engl J Med (2012) 1.47
Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience (2006) 1.46
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther (2006) 1.46
Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev (2012) 1.45
Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev (2008) 1.44
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol (1998) 1.40
Adenosine signaling and function in glial cells. Cell Death Differ (2009) 1.39
Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J Clin Invest (2007) 1.37
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem (1998) 1.28
Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med (2011) 1.28
Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol (2011) 1.27
Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol Scand (1991) 1.27
Changes in GAD- and GABA- immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors. J Chem Neuroanat (1998) 1.26
Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev (2013) 1.26
Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem (2005) 1.24
Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol (1996) 1.24
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta (2010) 1.23
Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain (2014) 1.22
Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain (2014) 1.21
Internalization and desensitization of adenosine receptors. Purinergic Signal (2007) 1.21
Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci (2012) 1.21
Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J (2012) 1.20
Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A (1996) 1.20
Release of gamma-aminobutyric acid in the dorsal horn and suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery (1996) 1.19
Emerging adenosine receptor agonists. Expert Opin Emerg Drugs (2007) 1.19
Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res (1997) 1.19
Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci (2010) 1.19
The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol (2009) 1.18
Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain (2005) 1.16
Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int (2007) 1.15
Adenosine receptors and cancer. Handb Exp Pharmacol (2009) 1.14
Direct cutaneous hyperalgesia induced by adenosine. Neuroscience (1990) 1.11
The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun (1997) 1.10
Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol (2007) 1.10
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther (2000) 1.09
Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse (1997) 1.09
The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther (2006) 1.09
Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci (1998) 1.09
Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB J (2008) 1.08
Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience (2005) 1.08
Microglia control neuronal network excitability via BDNF signalling. Neural Plast (2013) 1.08
A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs (2002) 1.07
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett (2008) 1.07
Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol (2003) 1.07
Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs (2001) 1.07
Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia (2009) 1.07
Adenosine receptors in health and disease. Adv Pharmacol (2011) 1.05
The A3 adenosine receptor: history and perspectives. Pharmacol Rev (2015) 1.05
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther (2011) 1.04
The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology (2008) 1.04
IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter. J Immunol (2006) 1.03
Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol (2002) 1.03
A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem (2003) 1.03
Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res (1998) 1.03
Balance of purines may determine life or death of retinal ganglion cells as A3 adenosine receptors prevent loss following P2X7 receptor stimulation. J Neurochem (2006) 1.03
Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol (2001) 1.02
Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. Cardiovasc Res (2002) 1.02
Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain (1998) 1.01
Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci (2009) 1.01
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol (2011) 0.99
Clinical application of adenosine and ATP for pain control. J Anesth (2005) 0.99
A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol (2009) 0.98
Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. Neuroscience (2002) 0.97
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. J Med Chem (1992) 0.97